Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Denise Fabian; Maria del Pilar Guillermo Prieto Eibl; Iyad Alnahhas; Nikhil Sebastian; Pierre Giglio; Vinay Puduvalli; Javier Gonzalez; Joshua D. Palmer

doi:10.3390/cancers11020174

Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Denise Fabian, Maria del Pilar Guillermo Prieto Eibl, Iyad Alnahhas, Nikhil Sebastian, Pierre Giglio, Vinay Puduvalli, Javier Gonzalez, Joshua D. Palmer

Research output: Contribution to journal › Review article › peer-review

195 Scopus citations

Abstract

Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

Original language	English
Article number	174
Journal	Cancers
Volume	11
Issue number	2
DOIs	https://doi.org/10.3390/cancers11020174
State	Published - Feb 2019

Bibliographical note

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

GBM
Glioblastoma
TTF
Tumor treating fields

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers11020174

Cite this

@article{88f9d1f6a49d467ca566660ee71ecf88,

title = "Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review",

abstract = "Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.",

keywords = "GBM, Glioblastoma, TTF, Tumor treating fields",

author = "Denise Fabian and Eibl, \{Maria del Pilar Guillermo Prieto\} and Iyad Alnahhas and Nikhil Sebastian and Pierre Giglio and Vinay Puduvalli and Javier Gonzalez and Palmer, \{Joshua D.\}",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = feb,

doi = "10.3390/cancers11020174",

language = "English",

volume = "11",

number = "2",

}

TY - JOUR

T1 - Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF)

T2 - A review

AU - Fabian, Denise

AU - Eibl, Maria del Pilar Guillermo Prieto

AU - Alnahhas, Iyad

AU - Sebastian, Nikhil

AU - Giglio, Pierre

AU - Puduvalli, Vinay

AU - Gonzalez, Javier

AU - Palmer, Joshua D.

PY - 2019/2

Y1 - 2019/2

N2 - Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

AB - Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

KW - GBM

KW - Glioblastoma

KW - TTF

KW - Tumor treating fields

UR - http://www.scopus.com/inward/record.url?scp=85062386864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062386864&partnerID=8YFLogxK

U2 - 10.3390/cancers11020174

DO - 10.3390/cancers11020174

M3 - Review article

AN - SCOPUS:85062386864

SN - 2072-6694

VL - 11

JO - Cancers

JF - Cancers

IS - 2

M1 - 174

ER -

Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this